Literature DB >> 17998836

Patient education in gastro-oesophageal reflux disease: a randomized controlled trial.

Jorgen Urnes1, Per G Farup, Stian Lydersen, Hermod Petersen.   

Abstract

OBJECTIVES: Gastro-oesophageal reflux disease (GORD) is chronic, affects 8-20% of the population, impairs quality of life (QoL) and generates substantial health-related costs. Patient education is intended to improve patients' disease-related competency, potentially enabling them to deal more efficiently with their disease, eventually improving QoL and reducing healthcare cost. This study aimed to investigate the effects of a group-based education programme for patients with mild GORD.
METHODS: Patients with GORD were randomly allocated to education (n=102) or control (n=109). The education programme was designed as a structured dialogue conveying medical information about the pathophysiology and prognosis, pharmacological and nonpharmacological treatment of GORD, patients' rights and use of healthcare. Outcomes were measured using general QoL [General Health Questionnaire-30 (GHQ-30)], disease-specific QoL [Digestive Symptoms and Impact Questionnaire (DSIQ)], global QoL and healthcare use at 2 and 12 months after the educational programme.
RESULTS: No statistically significant differences were found in GHQ-30, DSIQ or global QoL at 2 or 12 months' follow-up between the GORD-education group and controls. In the GORD-education group, patients who had completed primary school education only showed improved QoL at 12 months on both GHQ and DSIQ, whereas patients who had completed advanced schooling showed no change. No difference was found between the groups in their use of healthcare.
CONCLUSION: A group-based education programme for patients with mild GORD showed no effect on QoL or use of healthcare. Subgroup analyses showed improved QoL only in patients with primary school education, who had been allocated to GORD education.

Entities:  

Mesh:

Year:  2007        PMID: 17998836     DOI: 10.1097/MEG.0b013e3282f163dc

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  7 in total

1.  Counselling by primary care physicians may help patients with heartburn-predominant uninvestigated dyspepsia.

Authors:  Pierre Paré; Joanna Lee; Ian A Hawes
Journal:  Can J Gastroenterol       Date:  2010-03       Impact factor: 3.522

2.  The Effect of Group-Based Education on Knowledge and Adherence to a Gluten-Free Diet in Patients with Celiac Disease: Randomized Controlled Clinical Trial.

Authors:  Zahra Akbari Namvar; Reza Mahdavi; Masood Shirmohammadi; Zeinab Nikniaz
Journal:  Int J Behav Med       Date:  2021-01-08

3.  Non-pharmacological intervention for gastro-oesophageal reflux disease in primary care.

Authors:  Lesley B Dibley; Christine Norton; Roger Jones
Journal:  Br J Gen Pract       Date:  2010-12       Impact factor: 5.386

4.  The Degree of Disease Knowledge in Patients with Gastroesophageal Reflux Disease: A Multi-center Prospective Study in Korea.

Authors:  In Du Jeong; Moo In Park; Sung Eun Kim; Beom Jin Kim; Sang Wook Kim; Jie-Hyun Kim; Hye Young Sung; Tae-Hoon Oh; Yeon Soo Kim
Journal:  J Neurogastroenterol Motil       Date:  2017-07-30       Impact factor: 4.924

5.  The effect of group-based education on gastrointestinal symptoms and quality of life in patients with celiac disease: randomized controlled clinical trial.

Authors:  Zahra Akbari Namvar; Reza Mahdavi; Masood Shirmohammadi; Zeinab Nikniaz
Journal:  BMC Gastroenterol       Date:  2022-01-11       Impact factor: 3.067

6.  Assessing the Degree of Gastroesophageal Reflux Disease (GERD) Knowledge Among the Riyadh Population.

Authors:  Omalkhaire M Alshaikh; Issa M Alkhonain; Muath S Anazi; Albaraa A Alahmari; Feras O Alsulami; Abdulrhman A Alsharqi
Journal:  Cureus       Date:  2021-11-14

7.  Disease knowledge after an educational program in patients with GERD--a randomized controlled trial.

Authors:  Jorgen Urnes; Hermod Petersen; Per G Farup
Journal:  BMC Health Serv Res       Date:  2008-11-13       Impact factor: 2.655

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.